Compare Cassava Sciences Inc (FLNA) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Teradyne, Inc. — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Teradyne, Inc. trades at $323.44 (market cap $53.56B). The key difference: Teradyne, Inc. is far larger — about 1007.9× Cassava Sciences Inc's market cap, and Teradyne, Inc. pays a 0.15% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | TER | |
|---|---|---|
Market Cap | $53.14M | $53.56B |
Sector | Health | Technology |
52-Week High | $4.64 | $483.84 |
52-Week Low | $1.09 | $90.15 |
Enterprise Value | -$33.43M | $53.39B |
Dividend Yield | — | 0.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Teradyne (TER) trades at $353.23, up 3.55% today, with a bearish technical signal but strong fundamental performance. Recent earnings beats and a 64.52% analyst buy rating support optimism, though high valuation ratios like a P/E of 63.47 and negative net cash flow trends pose concerns. The stock is positioned near its pivot point of $354, with support at $347 and resistance at $360.
Outlook: Growth driven by AI and semiconductor testing demand offers upside to the $453.60 consensus target, but elevated valuations and cash flow challenges present risks. Investors should weigh robust profitability against potential volatility from market sentiment and execution hurdles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
